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Isovaleric acidemia (IVA) is an inborn error of leucine metabolism that can cause signiﬁcant morbidity and mortality.
Since the implementation, in many states and countries, of newborn screening (NBS) by tandem mass spectrometry,
IVA can now be diagnosed presymptomatically. Molecular genetic analysis of the IVD gene for 19 subjects whose
condition was detected through NBS led to the identiﬁcation of one recurring mutation, 932CrT (A282V),
in 47% of mutant alleles. Surprisingly, family studies identiﬁed six healthy older siblings with identical genotype
and biochemical evidence of IVA. Our ﬁndings indicate the frequent occurrence of a novel mild and potentially
asymptomatic phenotype of IVA. This has signiﬁcant consequences for patient management and counseling.
With the implementation of newborn screening (NBS)
by tandem mass spectrometry (MS/MS), 120 metabolic
disorders can now be detected very early in life, which
allows for presymptomatic initiation of treatment of af-
fected individuals and prevention of mental retardation
or even death. Expanded NBS, however, also has led to
the identiﬁcation of individuals with mild and benign
variants of some disorders, which complicates the choice
of treatment for these infants as well as the genetic coun-
seling of families. To date, this has become an issue for
medium-chain acyl-CoA dehydrogenase and 3-methyl-
crotonyl-CoA carboxylase deﬁciencies (Andresen et al.
2001; Koeberl et al. 2003).
Isovaleric acidemia (IVA [MIM 243500]) is one auto-
somal recessive inborn error of leucine metabolism that
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is detectable by NBS by use of MS/MS. IVA is caused by
a deﬁciency of isovaleryl-CoA dehydrogenase (IVD [En-
zyme Commission number 1.3.99.10]), which catalyzes
the third step in the catabolism of leucine. IVD, a mem-
ber of the family of acyl-CoA dehydrogenases, is a ho-
motetrameric mitochondrial ﬂavoenzyme. The IVD gene
is located on chromosome 15q14-15 and consists of 12
exons that span ∼15 kb of DNA. IVA is considered a
severe, potentially life-threatening disorder that mani-
fests with acute neonatal encephalopathy in about half
of affected individuals and with recurrent episodes of
vomiting, lethargy, coma, and varying degrees of devel-
opmental delay in the other half of patients (Sweetman
and Williams 2001). IVD deﬁciency results in the ac-
cumulation of isovaleryl-CoA derivatives, and the bio-
chemical diagnosis is based on the detection of isoval-
erylglycine and other metabolites in urine and of iso-
valerylcarnitine in plasma and blood spots. In addition
to dietary protein restriction, therapy with carnitine and/
or glycine is recommended. Early diagnosis by NBS al-
lows immediate initiation of treatment and close mon-
itoring, particularly during times of illness. On the basis
of recent NBS reports, the incidence of IVA has a range
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Table 1
Genotypes and Biochemical Phenotypes of Subjects with IVA
METABOLITE (SAMPLE TYPE)
REFERENCE
RANGE
Patients with IVA Diagnosed by NBS, with Genotypeb
“SYMPTOMATIC PATIENTS
WITH IVA”A282V/A282V A282V/Non-A282V Non-A282V/Non-A282V
C5AC (NBS blood spots) (mmol/liter) !.3–.99
a 3.0 (2.7–4.0) [ ]np 4 2.4 (.8c–6.0) [ ]np 8 10 (6.9–21.7) [ ]np 5 …
Isovalerylglycine (urine) (mmol/mol creatinine) !10 51 (23–79) [ ]np 2 133 (15–195) [ ]np 8 630 (7–3,331) [ ]np 5 1,219 (685–4,541) [ ]np 9
C5AC (plasma) (mmol/liter) !.44 3.00 (.18–7.60) [ ]np 4 2.85 (.66–11.50) [ ]np 7 3.00 (.98–29.00) [ ]np 5 1.01 (.30–48.20) [ ]np 17
Isovalerylcarnitine (ﬁbroblasts) (mmol/g protein) !.12 ( )np 88 .25 (.24–.25) [ ]np 2 .55 (.15–.67) [ ]np 3 .23 [ ]np 1 1.01 (.82–3.09) [ ]np 8
Isovalerylcarnitine (lymphoblasts) (mmol/g protein) !.01 ( )np 11 .29 (.22–.37) [ ]np 2 .14 (.03–.81) [ ]np 4 .57 (.39–.75) [ ]np 2 .71 (.31–1.3) [ ]np 15
a Range of cutoff values in the laboratories where the analyses were performed.
b Genotypes and biochemical phenotypes of 19 patients with IVA diagnosed by NBS, compared with the biochemical phenotype of a group of patients with IVA diagnosed after they had
presented clinically (“symptomatic patients”). Median-values; ranges are provided in parentheses. C5AC p C5 acylcarnitine.
c For the patient with a C5AC concentration of .8 mmol/liter, the cutoff value of the screening laboratory was .6 mmol/liter.
Table 2
Genotypes of 19 Patients with IVA Diagnosed by NBS
Patient Allele 1 Allele 2
1 932CrT (A282V) 932CrT (A282V)
2 932CrT (A282V) 932CrT (A282V)
3 932CrT (A282V) 932CrT (A282V)
4 932CrT (A282V) 932CrT (A282V)
5 932CrT (A282V) 932CrT (A282V)
6 932CrT (A282V) 149GrA (R21H)a
7 932CrT (A282V) 149GrC (R21P)
8 932CrT (A282V) 262GrT (G59C)a
9 932CrT (A282V) 359GrA (G91E)a
10 932CrT (A282V) 436ArG (K117E)a
11 932CrT (A282V) 868GrA (G261R)a
12 932CrT (A282V) 870_871insGa
13 932CrT (A282V) IVS42TrC
14 125TrC (L13P) IVS2-1GrCa
15 149GrC (R21P) IVS8-2ArGa
16 149GrC (R21P) 851GrA (R255Q)a
17 943ArC (K286Q)a IVS35GrTa,b
18 1136TrC (F350S)a IVS35GrTb
19 358GrA (G91R)a NI
NOTE.—Nucleotide changes are shown; the corresponding
amino acid change of the mature protein is in parentheses.
The most common mutation (932CrT) is underlined. NIp
not identiﬁed.
a Novel mutations.
b By comparison of the sequence environment with the
wild-type sequence, by use of Splice Site Prediction byNeural
Network, this intronic variant is expected to affect RNA
splicing by compromising the splice-site consensus sequence.
from 1/62,500 live births in parts of Germany (Schulze
et al. 2003) to ∼1/250,000 in the United States (Zytko-
vicz et al. 2001; Chace et al. 2003).
To date, highly heterogeneous mutations in the IVD
gene have been characterized in patients with IVA, in-
cluding point mutations, frameshifts, and splice-site mu-
tations (Parimoo and Tanaka 1993; Vockley et al. 2000;
Ensenauer et al. 2003). A phenotype/genotype correla-
tion, however, has not been established for IVA. In the
present study, the spectrum of mutations in the IVD gene
in patients who received diagnosis by NBS was investi-
gated and correlated to the clinical and biochemical phe-
notype. All samples in this study were collected and an-
alyzed with the approval of Mayo Clinic’s institutional
review board.
Twelve patients with IVA from Germany and seven
patients from the United States, born between 1998 and
2004, were investigated. Eleven patients are females and
eight are males. Sixteen patients are white, two patients
are Arabic, and one patient is Hispanic. All patients re-
ceived diagnosis through expanded NBS by use of MS/
MS, which revealed mildly to markedly elevated con-
centrations of C5 acylcarnitine (table 1). Treatment for
IVA was begun upon diagnosis, and all patients (now 2
mo to 5 years of age [median age 1.9 years]) have de-
veloped appropriately. For all patients, follow-up bio-
chemical genetic testing included (1) plasma acylcarni-
tine analysis and (2) urine organic acid and/or acylgly-
cine analyses. These assays were performed using estab-
lished procedures (Rinaldo et al., in press). Diagnostic
values were observed for the characteristic IVA metab-
olites, and the extent of abnormalities showed a variable
pattern similar to that of the NBS C5 acylcarnitine con-
centrations (table 1).
To further characterize these patients,molecular genetic
analysis of the IVD gene was undertaken, by use of
genomic DNA extracted from ﬁbroblasts, whole blood,
or dried blood spots. All 12 exons, including part of the
ﬂanking intron sequences of the IVD gene, were am-
pliﬁed by use of PCR, with intron-located primers, under
standard conditions. Mutation analysis was performed
by direct sequencing of PCR-ampliﬁed fragments, by use
of an ABI PRISM 3730 XL DNA Analyzer (96-capillary
[Perkin Elmer Applied Biosystems]). Primer sequences are
available on request. Twelve missense mutations, four
splice-site mutations, and one frameshift mutation were
identiﬁed (table 2). Three missense mutations—932CrT,
149GrC, and 125TrC—and 1 splice-site mutation—
IVS42TrC—have been reported elsewhere in symp-
tomatic patients (Mohsen et al. 1998), whereas the re-
maining 13 mutations were novel. Notably, the 932CrT
(A282V) mutation was found in 18 (47%) of 38 of mu-
tant alleles from the individuals identiﬁed by NBS, in-
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Figure 1 Restriction-enzyme analysis for the detection of the
932CrT (A282V) mutation. The 213-bp product is cleaved into two
fragments, of 146 bp and 67 bp, in the presence of the wild-type
sequence (CC). The mutated sequence is not cleaved (see lanes CT and
TT).
cluding 5 homozygous for this mutation (table 2). Eleven
patients who carried the 932CrT mutation were white,
and two patients were Arabic. Previous in vitro kinetic
studies on puriﬁed recombinant A282V-mutant enzyme
have demonstrated a signiﬁcantly increasedKm of 27 mM
and a markedly decreased catalytic efﬁciency of 11.4
compared with wild-type enzyme (3.11 1mM #min
mM and 520 , respectively), which sub-1 1mM #min
stantiates functional impairment of the mutant enzyme
(Mohsen et al. 1998). Furthermore, the A282V mutant
showed thermal instability, a ﬁnding that might indicate
a potential risk for the development of symptoms,
mainly during times of febrile illnesses (Nasser et al.
2004).
Because of the high frequency of this mutation in our
study population, we genotyped 100 randomly selected
subjects born at the Mayo Clinic in Rochester, MN, who
had normal NBS results, by use of DNA extracted from
the original NBS blood spots. For this purpose, we de-
veloped a mutation-speciﬁc site-directed mutagenesis as-
say for the 932CrT allele on the basis of creation of a
new restriction endonuclease recognition site for BsaJI.
After ampliﬁcation by use of the forward primer (5′-
CTGGGATTCTGGCCTTCCCACGCTAGCATTTTG-
CCACCACACCCGGTGGTGGGATGAGGAGGTGC-
TCAC-3′) at 0.3 mM and a mutagenic reverse primer (the
altered base is underlined) (5′-CAGTTGAAGAGTACA-
TGTCAGCAAAAGCACTCGGCTCACCTGGAAGTG-
GCCGATCTTCTGGCCCAA-3′) at 0.3 mM, a restric-
tion site for BsaJI is introduced into the wild-type IVD
sequence that results in cleavage of the 213-bp product
by BsaJI into two fragments, of 146 bp and 67 bp. The
mutated sequence remains undigested by this enzyme.
Fragments were separated by gel electrophoresis on a
3% Nusieve/agarose gel. The assay was validated by
DNA from dried blot spots previously shown by se-
quence analysis to harbor the 932CrT mutation on one
or both IVD gene alleles (ﬁg. 1). The 932CrT mutation
was not detected in any of the 100 randomly selected
individuals with normal NBS test results.
To determine the enzymatic activity of IVD, trans-
formed lymphocytes of ﬁve patients (homozygosity for
932CrT in two patients, compound heterozygosity for
932CrT and another mutation in one patient, and com-
pound heterozygosity for different mutations in two pa-
tients) were investigated using the anaerobic electron-
transferring ﬂavoprotein ﬂuorescence reduction assay
(Frerman and Goodman 1985). In all cases, no enzyme
activity was detected. To further delineate the biochemi-
cal effect of the IVD gene mutations in our patients, the
accumulation of isovalerylcarnitine was analyzed in a
culture medium of ﬁbroblasts or transformed lympho-
cytes, after incubation with palmitic acid, L-carnitine,
and isotopically labeled L-valine and L-isoleucine. Simi-
lar to assays described elsewhere (Roe and Roe 1999;
Shen et al. 2000), skin ﬁbroblast or Epstein-Barr virus–
transformed lymphocyte cultures from the patients, a
healthy control, and an IVD-deﬁcient control individual
were grown in triplicate in T25 ﬂasks to ∼90% con-
ﬂuency. Culture medium was then removed, and 3 ml
of modiﬁed MEM (Modiﬁed RPMI 1640 with L-glu-
tamine and without isoleucine and valine [JRH Biosci-
ences]) was added. This incubationmediumcontains fatty
acid–free BSA (200 mg/dl), palmitic acid (0.2 mmol/li-
ter), L-carnitine (0.4 mmol/liter [Sigma]), and isotopi-
cally labeled L-valine (0.8 mmol/liter U-13C-L-valine) and
L-isoleucine (U-13C-L-isoleucine [Cambridge Isotope Lab-
oratories]). After 72 h of incubation at 37C, the medium
was collected from each ﬂask for acylcarnitine analysis
(Shen et al. 2000). The remaining cells were gently
washed in PBS (Dulbecco’s PBS [Cellgro by Mediatech])
and were harvested by trypsinization (0.25 ml 0.25%
trypsin-EDTA [Life Technologies]). Protein content was
measured in all cell pellets after sonication, by use of
the method described by Lowry et al. (1951), and the
concentration of isovalerylcarnitine in the cell medium
was normalized to the protein concentration.
All patient cell lines accumulated increased levels of
isovalerylcarnitine in the cell medium, as compared with
normal controls (table 1), regardless of whether ﬁbro-
blasts or lymphoblasts were used. Four newborns who
were homozygous for the 932CrT mutation had iso-
valerylcarnitine concentrations with a range of 0.2–0.4
mmol/g protein (table 1). In contrast, ﬁbroblast cultures
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available from patients who had previously received
diagnoses of IVA after clinical manifestation (“symp-
tomatic patients”) ( ) produced isovalerylcarnitinenp 8
concentrations 10.4 mmol/g protein, whereas 93% of
lymphoblast cultures from such patients ( ex-np 15)
ceeded that value (table 1). No patient in this group
carried the 932CrT mutation. Overall, the differences
in isovalerylcarnitine concentrations between the group
of newborns who were either homozygous or compound
heterozygous for the 932CrT mutation and the symp-
tomatic patients were statistically signiﬁcant for both
ﬁbroblasts (Wilcoxon rank sum test; ) andP ! .0020
lymphoblasts ( ).P ! .0091
Review of the initial NBS results also revealed a cor-
relation with the genotype. The C5 acylcarnitine concen-
tration in the dried blood spots of newborns carrying
the 932CrT mutant allele, in either homozygous or
compound heterozygous fashion, was at least 1.3#
above the cutoff value of the individual screening lab-
oratories (table 1). However, the C5 acylcarnitine con-
centration in NBS bloods spots of these patients was
signiﬁcantly lower than in those of newborns with two
different IVD gene mutations ( ) (table 1).P ! .0019
Individuals who harbored the 932CrT mutation also
had an abnormal urinary excretion of isovalerylglycine;
however, this was much less pronounced than in the
group of symptomatic patients ( ) ( ) (tablenp 9 P ! .0001
1). All patients were in a stable clinical condition when
specimens were collected. To avoid treatment artifacts,
all patients who received glycine supplementation were
excluded from this analysis. Plasma C5 acylcarnitine
concentrations did not reliably differentiate between the
patients carrying the 932CrT mutation and the symp-
tomatic patient group ( ) (table 1), whereas thisP ! .2037
parameter generally allowed differentiation between un-
affected individuals and patients with IVA. It is impor-
tant to note that all plasma samples were collected when
the patients were already being treated with oral L-car-
nitine supplements at variable doses (15–150 mg/kg
body weight per day); assessment of correlation be-
tween plasma C5 acylcarnitine concentration and patient
genotype was not possible.
These ﬁndings raise the possibility that IVD deﬁciency
can be associated with a mild or asymptomatic pheno-
type that is now detected by NBS. We are aware of two
patients, aged 4.5 and 14 years, who are compound
heterozygous (the 932CrT mutation on one allele and
different mutations on the second allele). They received
diagnoses at age 4 years, after a metabolic work-up for
mild developmental delay, but have not experienced
acute episodes of metabolic decompensation. It is un-
certain whether the presence of the 932CrT mutation
and a second mutation in the IVD gene explains their
clinical phenotype or whether there is an underlying as-
certainment bias. On the basis of previous in vitro stud-
ies of this variant enzyme (Mohsen et al. 1998; Nasser
et al. 2004), we understand that it is possible that in-
dividuals homozygous for this allele or compound mu-
tant for it and another defective allele are at risk of
having acute metabolic crises when exposed to common
stressors such as fever and prolonged fasting.
To determine whether older siblings of our patients
might have the same genotype and biochemical ﬁndings,
24 asymptomatic siblings from 11 families were evaluated
by urine acylglycine and/or plasma acylcarnitine analy-
ses followed by mutation analysis. Eight of these families
had a newborn who was either homozygous ( ornp 2)
compound heterozygous ( ) for the 932CrT mu-np 6
tation. One additional child with a similar biochemical
phenotype and identical genotype was identiﬁed in each
of the two families with newborns homozygous for the
932CrT mutation and in four families with newborns
carrying one copy of the mutation and a second muta-
tion in the other allele. Each of the siblings, aged 3, 4,
6, 7, 8, and 11 years at the time of identiﬁcation, had
normal development and remained asymptomatic dur-
ing episodes of common pediatric illnesses. Study of the
families without at least one copy of the 932CrT mu-
tation did not disclose additional siblings with IVA.
Overall, our results suggest that individuals with IVD
deﬁciency discovered by NBS and who have at least one
copy of a 932CrT (A282V) mutant allele can exhibit a
mild phenotype or be free of symptoms throughout child-
hood. This is a major departure from our previous un-
derstanding of the natural history of IVA; there are ob-
vious implications for the management and genetic
counseling of individuals identiﬁed through NBS, which
include the need for genotyping of the IVD gene in the
early stages of follow-up. The expansion of NBS has led
to the identiﬁcation of mild and potentially benign forms
of disorders heretofore considered to have more consis-
tently serious implications. Our ﬁndings for IVD deﬁ-
ciency lead to a novel variation of this problem.Whereas
appropriate and speciﬁc information on the nature of a
disorder identiﬁed by NBS leads to a higher rate of pa-
rental satisfaction and to reduced stress levels, the op-
posite is true for false-positive results (Waisbren et al.
2003). Accordingly, dealing with situations inwhich long-
term outcome is uncertain requires particular care inman-
agement and counseling, to avoid unnecessary stress and
anxiety. This is complicated further by the fact that C5
acylcarnitine represents a mixture of isomers—namely,
isovalerylcarnitine, 2-methylbutyrylcarnitine, and piva-
loylcarnitine—that cannot be differentiated by MS/MS
analysis, as applied in the NBS setting. 2-Methylbutyryl-
carnitine is elevated in patients with 2-methylbutyryl-
glycinuria, a recently discovered inborn error of isoleu-
cine catabolism (Andresen et al. 2000; Gibson et al.
2000), whereas pivaloylcarnitine is derived from pivalic
Figure 2 Algorithm for the diagnostic evaluation of newborns with an elevated C5 acylcarnitine concentration in an NBS blood spot. An
asterisk (*) indicates that NBS was not available as a clinical test (research only). AC p acylcarnitine analysis; AG p acylglycine analysis;
C5AC p C5 acylcarnitine; H p abnormally elevated; IVC p isovalerylcarnitine; IVG p isovalerylglycine; MBC p 2-methylbutyrylcarnitine;
MBG p 2-methylbutyrylglycine; N p normal; ND p 932CrT mutation not detected; OA p organic acid analysis; PVA p pivalic acid (a
component of several antibiotic medications [Abdenur et al. 1998]); SBCAD-Dp short/branched-chain acyl-CoA dehydrogenase deﬁciency (2-
methylbutyrylglycinuria).
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acid, a component of several antibiotics (Abdenur et al.
1998).
The present study shows that a mild elevation of the
C5 acylcarnitine concentration in NBS blood spots does
not rule out a diagnosis of IVA, as previously hypothe-
sized (Matern et al. 2003). Urine acylglycine and organic
acid analyses are necessary ﬁrst steps in the differentiation
between these inborn errors of branched-chain aminoacid
(BCAA) metabolism and a false-positive result due to
medication, as illustrated in the algorithm in ﬁgure 2.
In vitro study of BCAA metabolism on either ﬁbroblasts
or lymphoblasts is a useful and sometimes necessary next
step for conﬁrmation of the diagnosis and for detection
of functional differences between individuals carrying
the 932CrT mutation and symptomatic patients. These
investigations are ultimately key for deﬁnition of the
clinical and biochemical phenotype in individuals car-
rying the 932CrT mutant IVD gene allele.
In summary, our ﬁndings suggest the existence of a
new, mild phenotype of IVA, detected by NBS, that is
associated with a 932CrT mutation in the IVD gene;
however, the long-term implications of this mutation re-
quire further study. To this end, patients who receive di-
agnosis ofmild IVA outside of infancy should be evaluated
for the presence of the 932CrT mutation and should be
characterized carefully at the molecular and biochemical
levels. We recommend early genotyping and sibling
evaluation of all new cases of IVA that are diagnosed
by NBS.
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